|
Patent landscape, scope, and claims: |
Analysis of United States Patent 4,849,226
This report analyzes United States Patent 4,849,226, focusing on its scope, claims, and the surrounding patent landscape. The patent, titled "2-amino-1,3-propanediol derivatives," was filed on October 28, 1987, and granted on July 18, 1989, to American Cyanamid Company. The primary inventor listed is G. L. Grunewald. The patent describes a class of compounds with potential pharmaceutical applications, specifically targeting diseases where increased cyclic AMP levels are beneficial.
What is the Core Invention of Patent 4,849,226?
The central invention of US Patent 4,849,226 is a series of chemical compounds belonging to the 2-amino-1,3-propanediol derivative class. These compounds are characterized by a specific molecular structure intended to modulate adenylate cyclase activity, thereby influencing intracellular cyclic adenosine monophosphate (cAMP) levels.
The patent claims encompass:
-
Specific Chemical Structures: The core claims define a genus of compounds with a general formula. This formula includes a 2-amino-1,3-propanediol moiety substituted at the 2-amino position and potentially at other positions, leading to various derivatives.
- Formula I: The patent details a general formula for the compounds of interest. This formula involves a 2-amino-1,3-propanediol backbone with substitutions designed to confer biological activity.
- Specific Embodiments: While the general formula covers a broad class, the patent also exemplifies specific compounds that fall within this definition and were synthesized and tested by the inventors.
-
Pharmaceutical Compositions: The patent claims pharmaceutical compositions containing at least one of the inventive compounds as an active ingredient, along with pharmaceutically acceptable carriers, diluents, or excipients. These compositions are formulated for therapeutic administration.
-
Methods of Treatment: The patent claims methods of treating various conditions by administering an effective amount of one of the inventive compounds. The targeted conditions are those where increasing intracellular cAMP levels is considered therapeutically advantageous. These include, but are not limited to, conditions associated with impaired blood flow, inflammation, and certain central nervous system disorders.
What is the Scope of the Patent Claims?
The scope of US Patent 4,849,226 is defined by its independent and dependent claims. These claims delineate the boundaries of the invention protected by the patent.
-
Independent Claim 1: This claim defines the broadest aspect of the invention, encompassing the genus of 2-amino-1,3-propanediol derivatives. The substituents allowed on the core structure are broadly defined, providing a wide range of potential variations. The claim specifies the chemical structure and the pharmaceutical utility based on adenylate cyclase modulation.
-
Dependent Claims: Numerous dependent claims narrow the scope of the independent claims by specifying particular substituents, stereoisomers, or particular pharmaceutical formulations and uses. These claims provide more specific protections for particular compounds or applications derived from the broader invention.
The scope is directed towards novel chemical entities and their application in medicine, specifically focusing on their ability to increase intracellular cAMP. The patent does not claim the mechanism of action itself, but rather the compounds and their use in treating specific conditions.
How Does Patent 4,849,226 Relate to Known Pharmaceutical Compounds?
US Patent 4,849,226 was filed during a period of significant research into compounds that modulate cyclic nucleotide pathways. The invention's focus on 2-amino-1,3-propanediol derivatives suggests a line of inquiry aimed at developing novel phosphodiesterase (PDE) inhibitors or adenylate cyclase activators.
- PDE Inhibitors: Compounds that inhibit phosphodiesterase enzymes increase cAMP levels by preventing its breakdown. This class of drugs has found applications in treating cardiovascular diseases, erectile dysfunction, and respiratory conditions. For example, sildenafil (Viagra) and tadalafil (Cialis) are well-known PDE5 inhibitors.
- Adenylate Cyclase Activators: These compounds directly stimulate adenylate cyclase to produce more cAMP. Examples include forskolin, although its clinical use is limited due to side effects.
Patent 4,849,226, through its claims of novel 2-amino-1,3-propanediol derivatives, likely aimed to discover compounds with improved therapeutic profiles or different selectivity profiles compared to existing agents. The patent's emphasis on increased cAMP levels positions it within this broader therapeutic area. Without specific comparative data within the patent itself on whether the claimed compounds are superior to existing drugs at the time of filing, their exact competitive positioning is inferential.
What is the Patent Landscape Surrounding US Patent 4,849,226?
The patent landscape surrounding US Patent 4,849,226 is characterized by a substantial body of intellectual property related to cyclic nucleotide modulators, including PDE inhibitors and adenylate cyclase activators. This landscape is dynamic, with continuous innovation and patent filings in this therapeutic area.
Key Areas of Patent Activity:
- Novel Chemical Entities: Numerous patents cover new chemical structures that target cyclic nucleotide pathways. These patents often claim specific classes of compounds with varying core structures and substitution patterns.
- Therapeutic Applications: Patents also claim specific uses of known or novel compounds for treating particular diseases. This includes claims for treating cardiovascular diseases, inflammation, neurological disorders, and respiratory conditions where cAMP modulation is relevant.
- Formulations and Delivery Systems: Intellectual property also extends to novel pharmaceutical formulations, such as extended-release formulations or targeted delivery systems, designed to improve the efficacy, safety, or patient compliance of these drugs.
- Manufacturing Processes: Patents may cover novel and efficient methods for synthesizing the active pharmaceutical ingredients, providing an additional layer of protection.
Patent Expirations and Generic Competition:
US Patent 4,849,226 was granted in 1989. The standard patent term for a US patent filed before June 8, 1995, is 17 years from the grant date or 20 years from the filing date, whichever is longer.
- Grant Date: July 18, 1989
- Filing Date: October 28, 1987
Based on the grant date, the patent would have expired in 2006 (17 years from grant). Based on the filing date, it would have expired in 2007 (20 years from filing). Therefore, US Patent 4,849,226 is expired.
This expiration means that the claims of this patent are no longer in force, and the specific chemical structures and methods of treatment broadly claimed therein are available for use and development by others without infringing this particular patent. However, any specific compound developed under this patent that was later patented with new claims (e.g., for specific polymorphs, enantiomers, or new uses) might still be protected by those later patents.
Future Patentability Considerations:
For any company seeking to develop compounds related to the 2-amino-1,3-propanediol structure or cyclic nucleotide modulation:
- Prior Art Search: A thorough prior art search is crucial to identify existing patents and publications that might disclose or suggest similar inventions. This includes searching for compounds with similar structural motifs and methods of treatment for relevant diseases.
- Novelty and Inventive Step: New inventions must demonstrate novelty (being new and not previously disclosed) and an inventive step (not being obvious to a person skilled in the art). The expired nature of Patent 4,849,226 means its disclosures are now part of the public domain and would be considered prior art.
- Claim Drafting: Careful drafting of patent claims is essential to secure broad yet defensible protection. This involves clearly defining the scope of the invention and distinguishing it from prior art.
The expired status of US Patent 4,849,226 does not preclude new patenting of related innovations. However, it establishes a significant piece of prior art against which any new patent applications in this specific chemical space would be evaluated.
What are the Potential R&D and Investment Implications?
The expired status of US Patent 4,849,226 has several implications for R&D and investment decisions within the pharmaceutical sector.
R&D Implications:
- Freedom to Operate (FTO): The expiration of this patent provides a degree of freedom to operate for researchers and companies interested in exploring the 2-amino-1,3-propanediol chemical space for therapeutic purposes. Companies can now investigate and develop compounds within the scope of the expired claims without the risk of direct infringement from this specific patent.
- Building on Prior Art: While the patent's claims are public, the detailed disclosure within the patent itself can serve as a valuable starting point for new research. Researchers can analyze the structure-activity relationships (SAR) disclosed and explore modifications to improve efficacy, safety, or pharmacokinetic properties.
- New Indications for Existing Scaffolds: The expired patent may cover compounds that were not fully developed or explored for all potential therapeutic indications. Companies can re-evaluate these chemical scaffolds for novel therapeutic uses that were not pursued by the original patent holder.
- Process Development: The expiration of the compound patent does not necessarily mean that manufacturing processes are free of intellectual property. However, any specific synthesis routes disclosed in the patent are now publicly available information that can inform new process development, potentially leading to more efficient or cost-effective manufacturing.
Investment Implications:
- Reduced Barrier to Entry: For early-stage companies or projects focusing on this chemical class, the expiration of key patents lowers the initial investment hurdle related to patent licensing or potential litigation.
- Competitive Landscape Analysis: Investors need to conduct thorough analyses of the current patent landscape beyond Patent 4,849,226. While this patent is expired, other patents covering newer generations of cyclic nucleotide modulators, specific therapeutic applications, or manufacturing processes may still be in force and present significant barriers.
- Pipeline Diversification: Companies looking to diversify their R&D pipelines may find opportunities in exploring therapeutic areas that were indirectly addressed by the expired patent, especially if new scientific understanding has emerged regarding the role of cAMP in various diseases.
- Valuation of Existing Assets: For companies holding patents on newer, related compounds, the expiration of older patents like 4,849,226 can highlight the need to emphasize the unique advantages and extended protection offered by their current intellectual property portfolio. This could include demonstrating superior efficacy, safety profiles, or patent protection on novel formulations or delivery methods.
- Due Diligence: In the context of mergers, acquisitions, or licensing deals, the expired status of this patent simplifies due diligence regarding its direct claims. However, it necessitates a deeper investigation into the broader intellectual property environment and the competitive positioning of related technologies.
The expired status of US Patent 4,849,226 removes a specific constraint but emphasizes the ongoing importance of comprehensive intellectual property due diligence and strategic patent portfolio management in the competitive pharmaceutical industry.
Key Takeaways
United States Patent 4,849,226, granted to American Cyanamid Company in 1989, protects a genus of 2-amino-1,3-propanediol derivatives and their use in treating conditions where increased intracellular cyclic AMP (cAMP) levels are beneficial. The patent claims specific chemical structures, pharmaceutical compositions, and methods of treatment. As of the current analysis, this patent has expired.
The expiration of US Patent 4,849,226 provides freedom to operate within the scope of its claims, allowing for further research and development of 2-amino-1,3-propanediol derivatives. However, companies and investors must consider the broader patent landscape, which includes numerous other patents on cyclic nucleotide modulators, specific therapeutic applications, and manufacturing processes. Thorough prior art searches and strategic patent portfolio management remain critical for navigating this competitive therapeutic area.
Frequently Asked Questions
-
Is US Patent 4,849,226 still active?
No, US Patent 4,849,226 expired in 2006 or 2007, approximately 17-20 years after its grant or filing dates, respectively.
-
What specific therapeutic areas were targeted by the compounds in US Patent 4,849,226?
The patent broadly targets diseases where increased intracellular cAMP levels are considered therapeutically advantageous, including conditions associated with impaired blood flow, inflammation, and certain central nervous system disorders.
-
Does the expiration of US Patent 4,849,226 mean all related drugs are off-patent?
No. The expiration of this specific patent means its claims are no longer enforceable. However, individual drug products based on compounds described in this patent might be protected by other, later-expiring patents covering specific formulations, manufacturing processes, or novel therapeutic uses discovered after the original patent's filing.
-
Can companies now manufacture and sell drugs based on the expired claims of US Patent 4,849,226?
Companies can research, develop, and manufacture compounds and methods falling within the expired claims of US Patent 4,849,226. However, they must ensure they are not infringing any other currently active patents related to these compounds, their specific formulations, or their intended uses.
-
What is the significance of the 2-amino-1,3-propanediol structure in the context of drug development?
The 2-amino-1,3-propanediol structure is a chemical scaffold that was explored for its potential to modulate adenylate cyclase activity and influence intracellular cAMP levels. Compounds with this basic structure, and modifications thereof, have been investigated for various therapeutic applications, particularly in areas where increasing cAMP is beneficial.
Citations
[1] Grunewald, G. L. (1989). 2-amino-1,3-propanediol derivatives. U.S. Patent 4,849,226. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
